← back to search

Federica Piccioni

Broad Institute ·
Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include Fibroblast Growth Factor Research, Protein Degradation and Inhibitors, CRISPR and Genetic Engineering, and Cancer Genomics and Diagnostics.
h-index
46
citations
12,358
works
361
NIH funding
primary concept
Medicine
email

Recent publications

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants
Nature Communications 2024cited by 28position: middledoi
Genome-wide CRISPR-Cas9 knockout screens identify DNMT1 as a druggable dependency in sonic hedgehog medulloblastoma
Acta Neuropathologica Communications 2024cited by 12position: middledoi
Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors
Genome biology 2024cited by 6position: middledoi
Natural variation in gene expression and viral susceptibility revealed by neural progenitor cell villages
Cell stem cell 2023cited by 110position: middledoi
BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Cancer Discovery 2022cited by 62position: middledoi
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation
Nature Communications 2022cited by 56position: middledoi
Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state
Nature Communications 2022cited by 36position: middledoi
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma
Cancer Cell 2021cited by 113position: middledoi
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Clinical Cancer Research 2020cited by 184position: middledoi
Genome-wide CRISPR and small-molecule screens uncover targetable dependencies in ATRT
bioRxiv (Cold Spring Harbor Laboratory) 2020cited by 3position: middledoi
LGG-35. FUNCTIONAL GENOMIC APPROACHES TO IDENTIFY THERAPEUTIC TARGETS IN <i>MYB</i> AND <i>MYBL1</i> EXPRESSING PEDIATRIC LOW-GRADE GLIOMAS
Neuro-Oncology 2020cited by 0position: middledoi
A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies
Science 2019cited by 427position: middledoi
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Cancer Cell 2019cited by 358position: middledoi
A Compendium of Genetic Modifiers of Mitochondrial Dysfunction Reveals Intra-organelle Buffering
Cell 2019cited by 157position: middledoi
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
Nature Communications 2019cited by 60position: middledoi
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Cancer Discovery 2019cited by 40position: middledoi
Mutational processes shape the landscape of TP53 mutations in human cancer
Nature Genetics 2018cited by 590position: middledoi
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
Cancer Cell 2018cited by 93position: middledoi
Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer
Cell Reports 2018cited by 46position: middledoi
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Cell 2017cited by 3,651position: middledoi
Synergistic interactions with PI3K inhibition that induce apoptosis
eLife 2017cited by 30position: middledoi
High-throughput Phenotyping of Lung Cancer Somatic Mutations
Cancer Cell 2016cited by 224position: middledoi
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles
Cancer Discovery 2016cited by 187position: middledoi
Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers
Cell Systems 2016cited by 75position: middledoi
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Cell 2014cited by 754position: middledoi
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
Nature Genetics 2014cited by 381position: middledoi
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Nature 2013cited by 455position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David E. Root · Broad Institute12 papers (2013–2024)William C. Hahn · University of California System4 papers (2014–2019)Jens Schittenhelm · Universitätsklinikum Tübingen3 papers (2020–2024)John G. Doench · Broad Institute3 papers (2016–2019) · 3 papers (2020–2024)Amy Goodale · Massachusetts Institute of Technology3 papers (2019–2020)Foteini Tsiami · University of Tübingen3 papers (2020–2024)Ghazaleh Tabatabai · Goethe University Frankfurt3 papers (2020–2024)Aviv Regev · Moscow Institute of Thermal Technology2 papers (2018–2020)Manfred Claassen · University of Lausanne2 papers (2020–2024)Kimberly Stegmaier · Harvard University2 papers (2019–2021)Scott A. Armstrong · Harvard University2 papers (2019–2019)Cristiana Roggia · University of Tübingen2 papers (2020–2024)Linda S. Ross · Dana-Farber Cancer Institute2 papers (2019–2021)Bianca Walter · University of Tübingen2 papers (2020–2024)L A Haeusser · Heidelberg University2 papers (2020–2024)Nathanael S. Gray · Stanford University2 papers (2017–2021)Sepideh Babaei · McGill University Health Centre2 papers (2020–2024) · 2 papers (2020–2024)Gabriela Alexe · Broad Institute2 papers (2019–2021)